> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# BioNTech's BNT113 Misses First Of Two Main Goals In Head And Neck Cancer Trial
- URL: https://www.bullished.co/biontechs-bnt113-misses-first-of-two-main-goals-in-head-and-neck-cancer-trial-3658c42f/
- Published: 2026-10-13T20:22:37.000Z
- Updated: 2026-10-13T20:22:37.000Z
- Description: The trial continues toward an overall survival analysis that, under its design, could still make the outcome positive.
- Author: Matteo Parrino
- Tags: SEC Filings, BNTX, Industry: Healthcare

BioNTech said Tuesday that its mRNA cancer immunotherapy BNT113, paired with pembrolizumab, [did not show a statistically significant improvement](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000067/a991261013%5Fbntxbnt113xprim.htm?ref=bullished.co) in progression-free survival against pembrolizumab alone in the AHEAD-MERIT Phase 2/3 trial. The company furnished the announcement to the SEC on Form 6-K; the study continues toward its second main goal, overall survival.

## What the release says

AHEAD-MERIT tests BNT113 plus pembrolizumab against pembrolizumab alone as first-line treatment for unresectable recurrent or metastatic head and neck squamous cell carcinoma that is HPV16-positive and expresses PD-L1\. The Phase 3 part has two dual primary endpoints: progression-free survival (time before the cancer worsens) and overall survival.

The first missed. The Independent Data Monitoring Committee recommended the trial continue as planned to evaluate overall survival. BioNTech said it remains blinded to ongoing trial data under the trial's governance procedures.

Under the pre-specified statistical design, a statistically significant overall survival improvement would establish a positive trial outcome even though the progression-free survival endpoint was not met, the company said.

## What it changes

The outcome of the trial is now tied to the overall survival analysis. The release gives no date for it.

Prof. Özlem Türeci, BioNTech's Co-Founder and Chief Medical Officer, said the progression-free survival result "was [not statistically significant](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000067/a991261013%5Fbntxbnt113xprim.htm?ref=bullished.co) at this first analysis." She said the data "[show that it](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000067/a991261013%5Fbntxbnt113xprim.htm?ref=bullished.co) is engaging its intended therapeutic mechanism," and that overall survival "will be critical to fully assess the potential of this approach."

BioNTech shares closed at $89.01 at Tuesday's close, down 7.13% from the prior session, before the company's 4:08 p.m. ET SEC filing of the announcement. Its market value was $24.1 billion.

## The drug and the setting

BNT113 encodes a fixed set of antigens targeting two HPV16-derived antigens, the E6 and E7 proteins, frequently found on HPV16-positive tumor cells. The company says no HPV-targeted treatments are currently approved. The FDA gave BNT113 Fast Track Designation in January 2026.

About one third of head and neck squamous cell carcinoma cases are associated with HPV infection, the company said. BioNTech calls mRNA cancer immunotherapies a key pillar of its oncology strategy.

The overall survival analysis will decide whether AHEAD-MERIT is a positive trial under its own pre-specified design.

### Sources

- [Form 6-K — BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer](https://www.sec.gov/Archives/edgar/data/1776985/000177698526000067/a991261013%5Fbntxbnt113xprim.htm?ref=bullished.co) — SEC EDGAR
- [Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines](https://finance.yahoo.com/healthcare/articles/vaccine-stocks-rally-reports-u-141200740.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance